Functional Concept – Page 37

Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial

7 months ago talkbio0Tagged Cardiff Oncology, first-line, onvansertib, ORR, Phase 2, RAS, RAS-mutated

Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.

Eli Lilly Announces $15 Billion Share Buyback Plan and 15% Dividend Increase

7 months ago talkbio0Tagged dividend, Drug Industry, Eli, Eli Lilly, Increase, Market, Share Buyback

Eli Lilly, Share Buyback, Dividend Increase, Pharmaceutical Industry, Stock Market

AstraZeneca’s Calquence Combination Shows Promise in Chronic Lymphocytic Leukemia with Fixed-Duration Regimens

7 months ago talkbio0Tagged acalabrutinib, AMPLIFY, AstraZeneca, Calquence, Chronic Lymphocytic Leukemia, Clinical Trials, CLL, Fixed-Duration, obinutuzumab

AstraZeneca, Calquence, chronic lymphocytic leukemia, CLL, fixed-duration treatment, acalabrutinib, venetoclax, obinutuzumab, AMPLIFY trial

FDA Action Alert: Recent Developments on Unapproved Drugs and Prescription Drug Approvals

7 months ago talkbio0Tagged approvals, Azurity, Clinical action, Ionis, lexicon, Myers, Prescription procedure, squibb, unapproved, United States Food and Drug Administration

FDA Action Alert, Unapproved Drugs, Prescription Drug Approvals, Azurity Pharmaceuticals Inc., Bristol Myers Squibb, Ionis, Lexicon

BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets

7 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, crash, liver transaminitis, Obesity, Phase 2 Clinical Trials, Safety

BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

7 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile

Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch

7 months ago talkbio0Tagged cancer medicine, Cyclacel, development aspects, Financial cost, Financial Stress, Nasdaq, Risk, strategic alternatives

Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

7 months ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy

FDA Grants Accelerated Approval to Merus’ Bizengri for NRG1+ Lung and Pancreatic Cancers

7 months ago talkbio0Tagged Accelerated, Approved, Bizengri, Malignant neoplasm of lung, Malignant Neoplasms, Merus, N.V., NRG1 gene, Pancreatic carcinoma, United States Food and Drug Administration, zenocutuzumab-zbco

Bizengri, NRG1+ cancers, FDA accelerated approval, lung cancer, pancreatic cancer, zenocutuzumab-zbco, Merus N.V.

Mitsubishi Tanabe and Dewpoint Therapeutics Collaborate on $480M ALS Treatment Development

7 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, biobucks, Dewpoint Therapeutics, Mitsubishi, small molecule condensate modulator, Tanabe Pharma, TARDBP gene

ALS treatment, Dewpoint Therapeutics, Mitsubishi Tanabe Pharma Corporation, TDP-43, small molecule condensate modulator, biobucks deal